•The standard rituximab maintenance dosing of 500 mg every 6 months may be insufficient to maintain B-cell depletion in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
The percentage of patients with undetectable B cells was 100% in the high intensity group compared with 69% and 60% in the low and standard groups, respectively (P =.03). ANCA negativity did not appear to be significantly associated with dose regimen.
Standard RTX maintenance dosing intensity of 500 mg every 6 months may be inadequate to maintain B cell depletion in a significant number of patients. A target RTX dose intensity of greater than 3.3 mg [per day] is required to maintain B-cell depletion
Read More: Springer J, Funk R. Pharmacological response of rituximab based on dose intensity in maintenance therapy of ANCA-associated vasculitis. Presented at: ACR Convergence 2021; November 3-10, 2021. Abstract 0416.